Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 26,010 shares of the stock in a transaction on Friday, November 24th. The shares were sold at an average price of $20.00, for a total value of $520,200.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total value of $552,802.50.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $304,762.50.

Crispr Therapeutics AG (CRSP) traded up $0.01 during trading hours on Thursday, reaching $18.53. The company’s stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The business had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. Crispr Therapeutics’s revenue was up 54.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.77) earnings per share. equities research analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of brokerages recently commented on CRSP. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. SunTrust Banks reaffirmed a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a report on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Barclays reaffirmed a “buy” rating and issued a $29.00 target price on shares of Crispr Therapeutics in a report on Friday, September 8th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Monday, August 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $22.38.

A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its position in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC purchased a new position in shares of Crispr Therapeutics during the third quarter valued at about $193,000. Ark Investment Management LLC purchased a new position in shares of Crispr Therapeutics during the second quarter valued at about $206,000. Moloney Securities Asset Management LLC purchased a new position in shares of Crispr Therapeutics during the third quarter valued at about $235,000. Finally, Vanguard Group Inc. purchased a new position in shares of Crispr Therapeutics during the second quarter valued at about $273,000. 24.55% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Corp /De/ Celgene Sells 26,010 Shares of Crispr Therapeutics AG (CRSP) Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/07/corp-de-celgene-sells-26010-shares-of-crispr-therapeutics-ag-crsp-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.